TNFRSF8 and neoplasm: Finally, there was no statistical correlation between CD30 expression in DLBCL and tumour response to brentuximab vedotin in a phase 2 study, which included 49 relapsed or refractory DLBCL patients, although all the responders had quantifiable CD30 expression by computer assisted digital video analysis immunohistochemistry (cIHC).